|
|
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer
Identification No.)
|
Title of Each Class
|
Trading Symbol(s)
|
Name of Each Exchange On Which Registered
|
||
|
|
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
NovaBay Pharmaceuticals, Inc.
|
||
By:
|
/s/ Justin Hall
|
|
Justin Hall
|
||
Chief Executive Officer and General Counsel
|
Document And Entity Information |
Jun. 29, 2023 |
---|---|
Document Information [Line Items] | |
Entity, Registrant Name | NovaBay Pharmaceuticals, Inc. |
Document, Type | 8-K |
Document, Period End Date | Jun. 29, 2023 |
Entity, Incorporation, State or Country Code | DE |
Entity, File Number | 001-33678 |
Entity, Tax Identification Number | 68-0454536 |
Entity, Address, Address Line One | 2000 Powell Street, Suite 1150 |
Entity, Address, City or Town | Emeryville |
Entity, Address, State or Province | CA |
Entity, Address, Postal Zip Code | 94608 |
City Area Code | 510 |
Local Phone Number | 899-8800 |
Title of 12(b) Security | Common Stock |
Trading Symbol | NBY |
Security Exchange Name | NYSE |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Entity, Emerging Growth Company | false |
Amendment Flag | false |
Entity, Central Index Key | 0001389545 |
-8?20$3;8T.P6BP^0"X99K>]9!:G
S'
MRV'C/_8E\N\47^2-GGO:,^ 1NG0PA=!W!5:JH\&6N0/T[W8=EIE(#ASEQ?DM&2F%)2S>,6]X
M\)ZY[A?YVE?5WL.F?GN!_136O0[Y4)NU? U!ZI8M/5!#-S)#OEF8W\=UGAP6
MNK;NU-#OL,2IIM?6GZ "33J'#\U>WUAT0FL[M:_:@:5$X!^)9NE_\M3X/U!+
M 0(4 Q0 ( ^(YE8TT._-8P, &4- 0 " 0 !N
M8GDM,C R,S V,CDN>'-D4$L! A0#% @ #XCF5HD ? /5! X2P !0
M ( !D0, &YB>2TR,#(S,#8R.5]D968N>&UL4$L! A0#%
M @ #XCF5CY"$G3V!0 0CP !0 ( !F @ &YB>2TR,#(S
M,#8R.5]L86(N>&UL4$L! A0#% @ #XCF5FHMF")Q! >2T !0
M ( !P X &YB>2TR,#(S,#8R.5]P